GSK's London-listed shares fell about 2% on Friday after the U.S. Food and Drug Administration approved only one of two ...

The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market ...

The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.

US regulators approved GSK Plc’s blood cancer drug, a decision that will allow the company to bring the medicine back to the ...

Walmsley took GSK back into oncology in 2018, after her predecessor Andrew Witty retreated from the specialism in 2015. The ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's blood cancer drug, Blenrep, in one combination ...

London: GSK plc and Syndivia, a private biotechnology company focused on next-generation ADCs, have announced an agreement ...

Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...

GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

GSK plc ( NYSE: GSK) and Syndivia on Monday announced an agreement granting GSK exclusive worldwide rights to develop and ...

--GSK has lately posted lower vaccine sales in China and the U.S., and faces pressure to show that its pipeline includes new blockbuster drugs to counter concerns about that slowdown, AJ Bell ...